New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
A new Cochrane review analyzing 22 randomized clinical trials involving 1,995 adults found intermittent fasting produces no clinically meaningful weight loss compared to traditional dietary advice or no intervention.
Recent research shows younger heart disease patients face unique parenting challenges, middle-aged healthy eating protects against cognitive decline, and timing evening meals three hours before bed improves cardiovascular markers.
Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.
A new Cochrane review of 22 randomized trials finds intermittent fasting produces little to no meaningful weight loss compared to traditional dietary advice or no intervention in overweight or obese adults.
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774065 |
Mechanical Ventilation in Obese Surgical Patients |
RECRUITING | NA |
| NCT07627919 |
Effect of Combined Resisted Training and Protein-based Diet on Frailty in Sarcopenic Elderly Women |
RECRUITING | NA |
| NCT07559240 |
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07479862 |
A Study of SA030 Injection in Overweight or Obese Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07411560 |
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese |
RECRUITING | PHASE1 |
| NCT07400588 |
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07363148 |
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults |
NOT_YET_RECRUITING | NA |
| NCT07219589 |
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants |
RECRUITING | PHASE1 |
| NCT07205900 |
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07175688 |
Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients |
COMPLETED |
